Creative Diagnostics has announced the expansion of its comprehensive range of Products for Hepatic Metabolism, offering pharmaceutical researchers and toxicologists new tools for conducting critical in vitro metabolism studies. The new line includes liver-specific fractions from various species, including Liver Cytosol, Liver Microsomes, and Liver S9 Fractions, designed to support more accurate drug development processes.
The liver plays a central role in human metabolism, processing both beneficial and harmful substances through four primary metabolic functions: carbohydrate metabolism, lipid and fatty acid metabolism, protein and amino acid metabolism, and drug metabolism. As the primary organ for drug metabolism and the main site of drug-induced toxicity, the liver accounts for over 50% of acute liver failure cases, which often leads to the withdrawal or restricted use of approved medications.
Beyond hepatotoxicity, metabolites generated in the liver circulate systemically to other tissues and organs, including the kidneys, heart, brain, intestines, and lungs, as well as tumors. This systemic distribution creates complex interactions that can either achieve desired therapeutic effects or lead to unintended toxic side effects. For example, the pre-chemotherapy drug ifosfamide produces both the intended antitumor metabolite, 4-hydroxy-IFO, and the nephrotoxic metabolite, chloroacetaldehyde, highlighting the need for careful evaluation of liver-organ interactions in drug development.
Creative Diagnostics now offers an extensive range of hepatic metabolism related products that enable researchers to study hepatic metabolic processes with high precision and reproducibility. The product line includes liver products from various species, such as humans, non-human primates, dogs, rats, rabbits, and minipigs, with core products including Liver Cytosol, Liver Microsomes, and Liver S9 Fractions. According to the company, these products provide comprehensive metabolic research solutions to address challenges encountered during drug development.
"Precise metabolomic analysis is the cornerstone of successful drug development," said the Creative Diagnostics project manager. "By offering a liver metabolism testing product line spanning multiple species, we help our clients in the pharmaceutical industry bridge the gap between in vitro testing and in vivo outcomes, ultimately reducing the risk of clinical failure."
Drug metabolism studies are essential during drug evaluation, and the expanded product line aims to accelerate research and development in the life sciences. Researchers can learn more about the full catalog of Products for Hepatic Metabolism by visiting https://qbd.creative-diagnostics.com/products-for-hepatic-metabolism.html.
